Keywords: erbitux, fails, ph, iii, pancreatic, cancer, trial

Erbitux fails in Ph III pancreatic cancer trial

Article | 16 April 2007

Print This

New York, USA-based firms ImClone Systems and Bristol-Myers Squibb say that a Phase III study of the anticancer drug Erbitux ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in